Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexeo Therapeutics, Inc. - Common Stock (NQ: LXEO )

7.230 +0.760 (+11.75%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 240,277
Open 6.530
Bid (Size) 6.500 (57)
Ask (Size) 7.500 (8)
Prev. Close 6.470
Today's Range 6.530 - 7.280
52wk Range 5.770 - 22.33
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024
LXEO stock results show that Lexeo Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
-51.25%
-51.25%
1 Month
-23.89%
-23.89%
3 Month
-36.07%
-36.07%
6 Month
-51.80%
-51.80%
1 Year
-34.27%
-34.27%

More News

Read More
Crude Oil Moves Lower; Goldman Sachs Posts Upbeat Results
Via Benzinga
Exposures Fossil Fuels
Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet
Via Benzinga
Why Top 4% Biotech Stock Lexeo Therapeutics Just Gave Up A Breakout
Via Investor's Business Daily
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Falls In July
Via Benzinga
Topics Stocks
Exposures US Equities
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
From Lexeo Therapeutics
Via GlobeNewswire
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
From Lexeo Therapeutics
Via GlobeNewswire
Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday
Via Benzinga
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
From Lexeo Therapeutics
Via GlobeNewswire
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
From Lexeo Therapeutics
Via GlobeNewswire
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
From Lexeo Therapeutics
Via GlobeNewswire
RBC Capital Maintains Outperform Rating for Lexeo Therapeutics: Here's What You Need To Know
Via Benzinga
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
From Lexeo Therapeutics
Via GlobeNewswire
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
From Lexeo Therapeutics
Via GlobeNewswire
Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
From Lexeo Therapeutics
Via GlobeNewswire
Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Fastenal Posts Upbeat Earnings, Joins NovoCure, Taiwan Semiconductor Manufacturing And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From LEXEO Therapeutics
Via GlobeNewswire
Marathon Digital, Canaan, CleanSpark And Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
From LEXEO Therapeutics
Via GlobeNewswire
LXEO Stock Earnings: Lexeo Therapeutics Reported Results for Q3 2023
Via InvestorPlace
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
From LEXEO Therapeutics
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.